{"id":67076,"date":"2026-06-02T13:47:53","date_gmt":"2026-06-02T05:47:53","guid":{"rendered":"https:\/\/flcube.com\/?p=67076"},"modified":"2026-06-02T13:47:53","modified_gmt":"2026-06-02T05:47:53","slug":"bms-camzyos-receives-fda-priority-review-for-adolescent-obstructive-hcm-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67076","title":{"rendered":"BMS’ Camzyos Receives FDA Priority Review for Adolescent Obstructive HCM Treatment"},"content":{"rendered":"\n

Bristol-Myers Squibb Co.<\/strong> (BMS, NYSE: BMY<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has accepted for review a supplemental New Drug Application (sNDA)<\/strong> for Camzyos (mavacamten)<\/strong> as a potential treatment for adolescents aged 12 to <18 years<\/strong> with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)<\/strong>. The FDA granted Priority Review<\/strong> with a Prescription Drug User Fee Act (PDUFA) decision date of September 30, 2026<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone & Development Status<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Bristol-Myers Squibb Co. (NYSE: BMY)<\/td><\/tr>
Drug Candidate<\/strong><\/td>Camzyos (mavacamten) \u2013 cardiac myosin inhibitor (CMI)<\/td><\/tr>
FDA Status<\/strong><\/td>sNDA accepted with Priority Review<\/td><\/tr>
Indication<\/strong><\/td>Symptomatic obstructive HCM in adolescents (12 to <18 years)<\/td><\/tr>
PDUFA Date<\/strong><\/td>September 30, 2026<\/td><\/tr>
Current Approval<\/strong><\/td>Adults with NYHA class II-III oHCM<\/td><\/tr>
Potential Distinction<\/strong><\/td>First CMI approved for adolescent oHCM<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 Phase 3 SCOUT-HCM Trial<\/h2>\n\n\n\n
Endpoint<\/th>Result<\/th>Significance<\/th><\/tr><\/thead>
Primary Endpoint<\/strong><\/td>Met with statistical significance<\/td>Clinically meaningful reduction in Valsalva LVOT gradient<\/td><\/tr>
LVOT Gradient Reduction<\/strong><\/td>Significant improvement vs. placebo at Week 28<\/td>Primary measure of oHCM severity<\/td><\/tr>
Safety Profile<\/strong><\/td>Similar to adult population<\/td>Consistent with known Camzyos safety<\/td><\/tr>
Cardiac Function<\/strong><\/td>No patients experienced LVEF <50%<\/strong><\/td>Critical safety parameter maintained<\/td><\/tr>
Study Population<\/strong><\/td>Symptomatic adolescents with oHCM<\/td>Addresses significant unmet need<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The SCOUT-HCM trial demonstrated that Camzyos effectively reduces left ventricular outflow tract obstruction\u2014the hallmark hemodynamic abnormality in oHCM\u2014while maintaining cardiac systolic function in adolescent patients.<\/p>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n